Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409351 | 1.00 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2398972 | 1.00 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL863894 | 0.92 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL863895 | 0.92 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3773280 | 0.92 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10606035 | 0.90 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9690449 | 0.90 | ACE (0.48) | CTSKCTSSKLK5FOLH1PPARG | |
| SCHEMBL5129671 | 0.88 | CTSK (0.47) | CTSKCTSSITGB3ITGA2B | |
| SCHEMBL17446712 | 0.88 | CTSL (0.56) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL2301394 | 0.88 | CYP1A2 (0.60) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436949-B | Tetradentate ligand, metal complex, and preparation methods and applications thereof | 上海巽田科技股份有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-122094956-A | 3CL protease inhibitors and methods thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122036541-A | Amino acid-based ionizable lipid compound, and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4709731-A1 | 3CLPRO INHIBITORS AND METHODS THEREOF | Agency for Science, Technology and Research (SG) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4638746-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638745-A1 | NOVEL FAS RNAI THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025217299-A1 | NOVEL LIPIDS CONTAINING DIKETOPIPERAZINE CORE, LIPID NANOPARTICLE CONTAINING THEREOF, AND METHODS OF USING THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2025-07-15 | — | — | US | disclosed |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2004-08-26 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6458948-B1 | MIXING A QUATERNARY AMMONIUM SALT HAVING A PARTICULAR TRIAZINE RING IN THE MOLECULES THEREOF, A CARBOXYLIC ACID COMPOUND AND A COMPOUND HAVING A NUCLEOPHILIC FUNCTIONAL GROUP, TO CONDENSE THE CARBOXYLIC ACID WITH THE COMPOUND HAVING THE NUCLEOPHILIC | TOKUYAMA CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| US-5552427-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-03 | — | — | US | disclosed |
| EP-0656210-A1 | Imidazole derivatives as glutaminose inhibitors | Takeda Chemical Industries, Ltd. (JP) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CTSK 541/4885CTSS 751/4885CYP1A2 827/4885 |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | CACNA1B, CACNA1G, CACNA1C | CTSK 3359/4885CTSS 3203/4885CYP1A2 1577/4885 |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | CTSK 4347/4885CTSS 4585/4885CYP1A2 2815/4885 |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | CACNA1E, CACNA1H, CACNA1D | CTSK 1472/4885CTSS 2672/4885CYP1A2 1285/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | CTSK 3995/4885CTSS 3842/4885CYP1A2 4508/4885 |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | CACNA1E, CACNA1D, CACNA1H | CTSK 1551/4885CTSS 3169/4885CYP1A2 1223/4885 |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | CTSK 2385/4885CTSS 2095/4885CYP1A2 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.